JACC. Heart failure最新文献

{"title":"Disparities Among Immigrants and Native Patients in Denmark With New-Onset Heart Failure With Reduced Ejection Fraction.","authors":"Sam Aiyad Ali, Naja Emborg Vinding, Jawad H Butt, Johanna Krøll, Johan E Larsson, Morten Schou, Emil L Fosbøl, Brian B Løgstrup, Inge Schjødt, Pardeep S Jhund, Lars Køber, Finn Gustafsson, Naveed Sattar, John J V McMurray, Søren Lund Kristensen","doi":"10.1016/j.jchf.2024.11.008","DOIUrl":"https://doi.org/10.1016/j.jchf.2024.11.008","url":null,"abstract":"<p><strong>Background: </strong>Worldwide, major health care variations exist in patients with heart failure (HF).</p><p><strong>Objectives: </strong>In this study, the authors sought to examine and compare immigrants grouped by region of origin and native Danish patients presenting with new-onset heart failure with reduced ejection fraction (HFrEF).</p><p><strong>Methods: </strong>The authors used data from the Danish Heart Failure Registry and administrative registries comprising information on medication, comorbidity, vital status, income level, and education. The co-primary outcomes were uptitration of guideline-directed medical therapy (GDMT) and a composite of HF hospitalization and all-cause death.</p><p><strong>Results: </strong>Overall, 55,918 patients were included, of whom 94.8% were native Danish patients, 3.0% originated from Europe/Central Asia, 1.1% from the Middle East/North Africa, 0.6% from South Asia, and 0.5% from other regions. Patients from the non-Western areas were around 10 years younger (median age 62 vs 72 years) and had more diabetes (38%-50% vs 20%) and ischemic heart disease (67%-74% vs 48%) and less atrial fibrillation (9%-15% vs 32%) compared with Danish patients (all P < 0.001). At 12 months' follow-up, no major differences in attainment of ≥50% target daily doses of GDMT were observed across groups. The crude 3-year cumulative risk of HF hospitalization or all-cause death ranged from 25% to 37% and was lowest for non-Western immigrants, although this difference does not persist in age- and sex-matched analyses.</p><p><strong>Conclusions: </strong>Patients in Denmark with HFrEF originating from non-Western parts of the world were younger and had more ischemic heart disease and diabetes and less atrial fibrillation compared with native Danish patients. The likelihood of GDMT uptitration at 12 months was similar to that of native Danish patients, whereas their risk of HF hospitalization or all-cause death was lower, although the difference between the 2 groups diminished in age- and sex-matched analyses.</p>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ventricular Reconstruction","authors":"Frederick G.P. Welt MD,&nbsp;James C. Fang MD","doi":"10.1016/j.jchf.2024.12.001","DOIUrl":"10.1016/j.jchf.2024.12.001","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 309-311"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143180872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"24-Month Outcomes of Endovascular Baroreflex Amplification With the MobiusHD Device in Heart Failure With Reduced Ejection Fraction","authors":"Kerstin Piayda MD, MSc ,&nbsp;Stefan Bertog MD ,&nbsp;Kolja Sievert MD ,&nbsp;Horst Sievert MD ,&nbsp;Tamaz Shaburishvili MD ,&nbsp;Irakli Gogorishvili MD ,&nbsp;Martin Rothman MD ,&nbsp;James L. Januzzi Jr. MD ,&nbsp;JoAnn Lindenfeld MD ,&nbsp;Gregg W. Stone MD","doi":"10.1016/j.jchf.2024.11.005","DOIUrl":"10.1016/j.jchf.2024.11.005","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 386-388"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth Differentiation Factor–15 Is Associated With Congestion-Related Anorexia and Weight Loss in Advanced Heart Failure","authors":"Luca Monzo MD, PhD ,&nbsp;Petr Jarolim MD, PhD ,&nbsp;Barry A. Borlaug MD ,&nbsp;Jan Benes MD, PhD ,&nbsp;Ivana Jurcova MD ,&nbsp;Dominik Jenca MD ,&nbsp;Katerina Kroupova MD ,&nbsp;Peter Wohlfahrt MD, PhD ,&nbsp;Martin Kotrc MD ,&nbsp;Vojtech Melenovsky MD, PhD","doi":"10.1016/j.jchf.2024.10.023","DOIUrl":"10.1016/j.jchf.2024.10.023","url":null,"abstract":"<div><h3>Background</h3><div>Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy.</div></div><div><h3>Objectives</h3><div>This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced heart failure with reduced ejection fraction (HFrEF).</div></div><div><h3>Methods</h3><div>In this observational, retrospective analysis, a total of 344 patients with advanced HFrEF (age 58 ± 10 years, 85% male, 67% NYHA functional class III), underwent clinical and echocardiographic examination, body composition evaluation by skinfolds and dual-energy x-ray absorptiometry, circulating metabolite assessment, Minnesota Living with Heart Failure Questionnaire, and right heart catheterization.</div></div><div><h3>Results</h3><div>The median GDF-15 level was 1,503 ng/L (Q1-Q3: 955-2,332 ng/L) (reference range: &lt;1,200 ng/L). Higher GDF-15 levels were associated with more prevalent anorexia and cachexia. Patients with higher GDF-15 had increased circulating free fatty acids and beta-hydroxybutyrate, lower albumin, cholesterol, and insulin/glucagon ratio, consistent with a catabolic state. Patients with higher GDF-15 had worse congestion and more severe right ventricular dysfunction. In multivariable Cox analysis, elevated GDF-15 was independently associated with risk of the combined endpoint of death, urgent transplantation, or left ventricular assist device implantation, even after adjusting for coexisting anorexia and cachexia (T3 vs T1 HR: 2.31 [95% CI: 1.47-3.66]; <em>P &lt;</em> 0.001).</div></div><div><h3>Conclusions</h3><div>In patients with advanced HFrEF, elevated circulating GDF-15 levels are associated with a higher prevalence of anorexia and cachexia, right ventricular dysfunction, and congestion, as well as an independently increased risk of adverse events. Further studies are warranted to determine whether therapies altering GDF-15 signaling pathways can affect metabolic status and clinical outcomes in advanced HFrEF.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 315-329"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes","authors":"Eperke Merkel MD ,&nbsp;Robert Hatala MD, PhD ,&nbsp;Mátyás Szigeti PhD ,&nbsp;Walter Schwertner MD ,&nbsp;Bálint Lakatos MD, PhD ,&nbsp;Anett Behon MD ,&nbsp;Kinga Goscinska-Bis MD ,&nbsp;Goran Milasinovic MD ,&nbsp;Roland Papp MD ,&nbsp;Mihály Ruppert MD, PhD ,&nbsp;László Sághy MD, PhD ,&nbsp;Marcell Clemens MD, PhD ,&nbsp;Scott D. Solomon MD ,&nbsp;Valentina Kutyifa MD, PhD ,&nbsp;Attila Kovács MD, PhD ,&nbsp;Annamária Kosztin MD, PhD ,&nbsp;Béla Merkely MD, PhD","doi":"10.1016/j.jchf.2024.09.011","DOIUrl":"10.1016/j.jchf.2024.09.011","url":null,"abstract":"<div><h3>Background</h3><div>In the BUDAPEST (Biventricular Upgrade on left ventricular reverse remodeling and clinical outcomes in patients with left ventricular Dysfunction and intermittent or permanent APical/SepTal right ventricular pacing)-CRT Upgrade randomized trial, the authors have demonstrated improved mortality and morbidity after cardiac resynchronization therapy (CRT) upgrade in patients with heart failure with reduced ejection fraction (HFrEF) with high right ventricular (RV) pacing burden.</div></div><div><h3>Objectives</h3><div>This substudy sought to examine the impact of CRT upgrade on symptoms, functional outcome, and exercise capacity.</div></div><div><h3>Methods</h3><div>In the BUDAPEST-CRT Upgrade trial, 360 HFrEF patients with pacemaker or implantable cardioverter-defibrillator (ICD) and ≥20% RV pacing burden were randomly assigned (3:2) to cardiac resynchronization therapy with defibrillator (CRT-D) upgrade (n = 215) or ICD (n = 145). The prespecified tertiary endpoints were changes in quality of life (QoL) (EQ-5D-3L), NYHA functional class, 6-minute walk test, and N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels.</div></div><div><h3>Results</h3><div>Up to 12 months, NYHA functional class improved in the CRT-D upgrade arm compared with ICD only (adjusted OR: 0.50 [95% CI: 0.32-0.80]; <em>P =</em> 0.003). A remarkable decrease was observed in NT-proBNP levels in the CRT-D arm (adjusted difference: −1,257 pg/mL [95% CI: −2,287 to −228 pg/mL]; <em>P =</em> 0.017). The progression of age-related worsening of QoL was moderated by CRT-D upgrade (EQ-5D-3L difference by each year: 0.015 [95% CI: 0.005-0.025]; <em>P</em> interaction = 0.003). However, exercise tolerance (6-minute walk test) remained unchanged in both groups.</div></div><div><h3>Conclusions</h3><div>HFrEF patients with pacemaker/ICD and ≥20% RV pacing burden receiving CRT upgrade showed a substantial improvement in NYHA functional class and decrease in natriuretic peptide levels, as compared with ICD alone. Moreover, CRT-D upgrade could moderate the progression of worsening of QoL attributed to ageing in this vulnerable, elderly patient population. (Biventricular Upgrade on left ventricular reverse remodeling and clinical outcomes in patients with left ventricular Dysfunction and intermittent or permanent APical/SepTal right ventricular pacing [BUDAPEST]-CRT Upgrade trial; <span><span>NCT02270840</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 265-273"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Heart Failure","authors":"Johan E. Larsson MD, PhD ,&nbsp;Maria Generosa Crespo-Leiro MD, PhD ,&nbsp;Finn Gustafsson MD, PhD","doi":"10.1016/j.jchf.2024.10.026","DOIUrl":"10.1016/j.jchf.2024.10.026","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 248-252"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143179806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcomes in Heart Failure","authors":"Gregg C. Fonarow MD ,&nbsp;Amber B. Tang MD","doi":"10.1016/j.jchf.2024.10.019","DOIUrl":"10.1016/j.jchf.2024.10.019","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 293-295"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143179805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can and Should LIVE Be Revived?","authors":"Michael I. Brener MD, MS,&nbsp;Daniel Burkhoff MD, PhD","doi":"10.1016/j.jchf.2025.01.001","DOIUrl":"10.1016/j.jchf.2025.01.001","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 312-314"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full issue PDF","authors":"","doi":"10.1016/S2213-1779(25)00002-2","DOIUrl":"10.1016/S2213-1779(25)00002-2","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages i-ccx"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143180846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy","authors":"Pablo Garcia-Pavia MD, PhD ,&nbsp;Ozlem Bilen MD ,&nbsp;Melissa Burroughs MD ,&nbsp;Juan Pablo Costabel MD ,&nbsp;Edileide de Barros Correia MD ,&nbsp;Anne M. Dybro MD, PhD ,&nbsp;Perry Elliott MBBS, MD ,&nbsp;Neal K. Lakdawala MD ,&nbsp;Amy Mann BA ,&nbsp;Ajith Nair MD ,&nbsp;Michael E. Nassif MD ,&nbsp;Steen H. Poulsen MD ,&nbsp;Patricia Reant MD, PhD ,&nbsp;P. Christian Schulze MD ,&nbsp;Andrew Wang MD ,&nbsp;Indrias Berhane PhD ,&nbsp;Stephen B. Heitner MD ,&nbsp;Daniel L. Jacoby MD ,&nbsp;Stuart Kupfer MD ,&nbsp;Fady I. Malik MD, PhD ,&nbsp;Michael A. Fifer MD","doi":"10.1016/j.jchf.2024.11.011","DOIUrl":"10.1016/j.jchf.2024.11.011","url":null,"abstract":"<div><div>Beta-blockers and nondihydropyridine calcium-channel blockers have been standard-of-care (SOC) medications for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), even though these agents do not directly affect the underlying pathophysiology of the disease. Cardiac myosin inhibitors act by decreasing the number of myosin heads binding to actin, reducing the pathologic hypercontractility of HCM, and have been shown to improve exercise capacity and alleviate symptoms in oHCM when added to SOC medications. Cardiac myosin inhibitors are currently considered as second-line therapy in the absence of head-to-head comparison studies vs SOC medications. The aim of the ongoing phase 3 study MAPLE-HCM (Metoprolol vs Aficamten in Patients With LVOT Obstruction on Exercise Capacity in HCM) is to fill this evidence gap by evaluating aficamten as both first-line therapy for newly diagnosed oHCM and as a monotherapy alternative for patients currently on SOC drugs. The authors describe the rationale, design, and baseline characteristics of patients in this study. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM [MAPLE-HCM]; <span><span>NCT05767346</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 346-357"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143180875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}